{
    "root": "e816b106-45b6-5c02-b36d-0aefc5ed354f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rivaroxaban",
    "value": "20231216",
    "ingredients": [
        {
            "name": "Rivaroxaban",
            "code": "9NDF7JZ4M3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "Croscarmellose Sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "Poloxamer 407",
            "code": "TUF2IVW3M2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "Polyethylene Glycol 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "Talc",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "Anhydrous Lactose",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        }
    ],
    "indications": {
        "text": "rivaroxaban tablets factor xa inhibitor indicated : reduce risk major cardiovascular events patients coronary artery disease ( cad ) ( 1.7 ) reduce risk major thrombotic vascular events patients peripheral artery disease ( pad ) , including patients recent lower extremity revascularization due symptomatic pad ( 1.8 )",
        "doid_entities": [
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "peripheral artery disease (DOID:0050830)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050830"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "cad pad : 2.5 mg orally twice daily without food , combination aspirin ( 75 100 mg ) daily ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rivaroxaban film-coated tablets , usp available strengths packages listed : 2.5 mg tablets yellow , round shape , biconvex coated tablet . engraved `` r `` `` 2.5 `` one side , plain side . tablets supplied packages listed : ndc 60505-6256-6 bottle containing 60 tablets ndc 60505-6256-5 bottle containing 500 tablets store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . keep reach children .",
    "adverseReactions": "rivaroxaban tablets contraindicated patients : active pathological bleeding [ ( 5.2 ) ] severe hypersensitivity reaction rivaroxaban tablets ( e.g . , anaphylactic ) [ ( 6.2 ) ]",
    "indications_original": "Rivaroxaban tablets \u00a0is a factor Xa inhibitor indicated: to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 )",
    "contraindications_original": "CAD or PAD: 2.5 mg orally twice daily with or without food, in combination with aspirin (75 to 100 mg) once daily ( 2.1 )",
    "warningsAndPrecautions_original": "Rivaroxaban film-coated tablets, USP\u00a0are\u00a0available in\u00a0the\u00a0strengths\u00a0and\u00a0packages listed below: \n                  2.5 mg tablets are yellow, round shape, biconvex coated tablet. Engraved \"R\" over \"2.5\" on one side, plain on the other side. \n                  The\u00a0tablets\u00a0are\u00a0supplied\u00a0in\u00a0the packages listed:\n                  NDC 60505-6256-6 Bottle containing 60 tablets\n                  NDC 60505-6256-5 Bottle containing 500 tablets\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. \n                  Keep out of the reach of children.",
    "adverseReactions_original": "Rivaroxaban tablets\u00a0are\u00a0contraindicated\u00a0in\u00a0patients\u00a0with: \n                  \n                     active pathological bleeding [see Warnings and Precautions (5.2)]\u00a0 \n                     severe hypersensitivity reaction to rivaroxaban tablets (e.g., anaphylactic reactions) [see Adverse Reactions (6.2)]",
    "drug": [
        {
            "name": "Rivaroxaban",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        }
    ]
}